Evidence map›Paper›PMID 34122778›Full record

ArticleJournal of extracellular vesicles2021

Early prediction of COVID-19 severity using extracellular vesicle COPB2.

Yu Fujita, Tokio Hoshina, Juntaro Matsuzaki, Yusuke Yoshioka, Tsukasa Kadota, Yusuke Hosaka, Shota Fujimoto, Hironori Kawamoto, Naoaki Watanabe, Kenji Sawaki and 11 more

Open access · goldAbstract read
In one paragraph

Article in Journal of extracellular vesicles, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. IsomiR stoichiometry changes as disease biomarkers.Molecular therapy. Nucleic acids · 2025
    Article
  7. Article
  8. Article
  9. Review
  10. CD66bJournal of extracellular vesicles · 2024
    Article
  11. 1-L Transcription of SARS-CoV-2 Spike Protein S1 Subunit.International journal of molecular sciences · 2024
    Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Extracellular Vesicles and Their Role in Lung Infections.International journal of molecular sciences · 2023
    Review
  17. Article
  18. Review
  19. A Review of Extracellular Vesicles in COVID-19 Diagnosis, Treatment, and Prevention.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 2 institutions in 1 country.

Yu FujitaDepartment of Translational Research for Exosomes The Jikei University School of Medicine Tokyo Japan.
Tokio HoshinaDepartment of Infectious Diseases and Infection Control The Jikei University School of Medicine Tokyo Japan.
Juntaro MatsuzakiDepartment of Molecular and Cellular Medicine Institute of Medical Science Tokyo Medical University Tokyo Japan.
Yusuke YoshiokaDepartment of Molecular and Cellular Medicine Institute of Medical Science Tokyo Medical University Tokyo Japan.
Tsukasa KadotaDivision of Respiratory Diseases Department of Internal Medicine The Jikei University School of Medicine Tokyo Japan.
Yusuke HosakaDivision of Respiratory Diseases Department of Internal Medicine The Jikei University School of Medicine Tokyo Japan.
Shota FujimotoDivision of Respiratory Diseases Department of Internal Medicine The Jikei University School of Medicine Tokyo Japan.
Hironori KawamotoDivision of Respiratory Diseases Department of Internal Medicine The Jikei University School of Medicine Tokyo Japan.
Naoaki WatanabeDivision of Respiratory Diseases Department of Internal Medicine The Jikei University School of Medicine Tokyo Japan.
Kenji SawakiDepartment of Infectious Diseases and Infection Control The Jikei University School of Medicine Tokyo Japan.
Yohei SakamotoDepartment of Infectious Diseases and Infection Control The Jikei University School of Medicine Tokyo Japan.
Makiko MiyajimaDepartment of Infectious Diseases and Infection Control The Jikei University School of Medicine Tokyo Japan.
Kwangyole LeeDepartment of Infectious Diseases and Infection Control The Jikei University School of Medicine Tokyo Japan.
Kazuhiko NakaharaiDepartment of Infectious Diseases and Infection Control The Jikei University School of Medicine Tokyo Japan.
Tetsuya HorinoDepartment of Infectious Diseases and Infection Control The Jikei University School of Medicine Tokyo Japan.
Ryo NakagawaOmiya City Clinic Saitama Japan.
Jun ArayaDivision of Respiratory Diseases Department of Internal Medicine The Jikei University School of Medicine Tokyo Japan.
Mitsuru MiyatoDepartment of Molecular and Cellular Medicine Institute of Medical Science Tokyo Medical University Tokyo Japan.
Masaki YoshidaDepartment of Infectious Diseases and Infection Control The Jikei University School of Medicine Tokyo Japan.
Kazuyoshi KuwanoDivision of Respiratory Diseases Department of Internal Medicine The Jikei University School of Medicine Tokyo Japan.
Takahiro OchiyaDepartment of Molecular and Cellular Medicine Institute of Medical Science Tokyo Medical University Tokyo Japan.
Jikei University School of Medicine · JPTokyo Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The clinical manifestations of COVID-19 vary broadly, ranging from asymptomatic infection to acute respiratory failure and death. But the predictive biomarkers for characterizing the variability are still lacking. Since emerging evidence indicates that extracellular vesicles (EVs) and extracellular RNAs (exRNAs) are functionally involved in a number of pathological processes, we hypothesize that these extracellular components may be key determinants and/or predictors of COVID-19 severity. To test our hypothesis, we collected serum samples from 31 patients with mild COVID-19 symptoms at the time of their admission for discovery cohort. After symptomatic treatment without corticosteroids, 9 of the 31 patients developed severe/critical COVID-19 symptoms. We analyzed EV protein and exRNA profiles to look for correlations between these profiles and COVID-19 severity. Strikingly, we identified three distinct groups of markers (antiviral response-related EV proteins, coagulation-related markers, and liver damage-related exRNAs) with the potential to serve as early predictive biomarkers for COVID-19 severity. As the best predictive marker, EV COPB2 protein, a subunit of the Golgi coatomer complex, exhibited significantly higher abundance in patients remained mild than developed severe/critical COVID-19 and healthy controls in discovery cohort (AUC 1.00 (95% CI: 1.00-1.00)). The validation set included 40 COVID-19 patients and 39 healthy controls, and showed exactly the same trend between the three groups with excellent predictive value (AUC 0.85 (95% CI: 0.73-0.97)). These findings highlight the potential of EV COPB2 expression for patient stratification and for making early clinical decisions about strategies for COVID-19 therapy.

Indexed as

BiomarkersCell-Free Nucleic AcidsCoatomer ProteinCOVID-19Extracellular VesiclesHumansRetrospective StudiesSARS-CoV-2Severity of Illness IndexBiomarkersCell-Free Nucleic AcidsCoatomer ProteinCOPB2 protein, humanbiomarkerCOVID‐19extracellular RNAextracellular vesicleSARS‐CoV‐2

Identifiers

PMID34122778
PMCPMC8172627
OpenAlexW3172804624

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.